Prognosis is separated into three groups. * Stage I<unk>  is rare and includes parosteal<unk>  or low-grade central<unk> . It has an excellent prognosis (>90%) with wide resection. * Stage II prognosis depends on the site of the tumor (proximal tibia, femur, pelvis, etc.), size of the tumor mass, and the degree of necrosis from neoadjuvant chemotherapy. Other pathological factors such as the degree of p-glycoprotein, whether the tumor is cxcr4-positive, or Her2-positive are also important, as these are associated with distant metastases to the lung. The prognosis for patients with metastatic<unk>  improves with longer times to metastases (more than 12 months to 4 months), a smaller number of metastases, and their resectability. It is better to have fewer metastases than longer time to metastases. Those with a longer length of time (more than 24 months) and few nodules (two or fewer) have the best prognosis, with a two-year survival after the metastases of 50%, five-year of 40%, and 10-year of 20%. If metastases are both local and regional, the prognosis is worse. * Initial presentation of stage III<unk>  with lung metastases depends on the resectability of the primary tumor and lung nodules, degree of necrosis of the primary tumor, and maybe the number of metastases. Overall survival prognosis is about 30%. Deaths due to malignant neoplasms of the bones and joints account for an unknown number of childhood cancer deaths. Mortality rates due to<unk>  have been declining at about 1.3% per year. Long-term survival probabilities for<unk>  have improved dramatically during the late 20th century and approximated 68% in 2009.
Osteosarcoma
Ewing's sarcoma
Osteoblastoma
Osteoma
Osteochondroma
Synovial sarcoma
Osteochondrosis
Bone cyst